Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Breast Cancer
In brief
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Aromatase inhibition therapy using letrozole, anastrozole, or exemestane may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether sorafenib is more effective than a placebo when given together with letrozole, anastrozole, or exemestane in treating metastatic breast cancer. PURPOSE: This randomized phase II trial is studying how well sorafenib works compared with a placebo when given together with letrozole, anastrozole, or exemestane in treating postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive metastatic breast cancer.
Key facts
- Study ID
- NCT00573755
- Run by
- Mayo Clinic
- People needed
- 4
- Starts
- 2007-12-01
- Expected to finish
- 2013-04-01
- Last updated by the study team
- 2016-02-05
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Arizona — Scottsdale, Arizona, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.